/PRNewswire/ Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and.
GPO Plus, Inc.: GPO Plus Announces Removal of Shell Risk Designation by OTC Markets
Las Vegas, Nevada (Newsfile Corp. - May 24, 2021) -
GPO Plus, Inc.
(OTCQB:
GPOX), a diversified corporation operating industry specific Group Purchasing Organizations (GPOs), announced today the Company s shell risk designation from OTC Markets has been removed, and the company has published its 3rd fiscal quarter results with a significant increase in gross revenue.
GPOX - Q3 Result
https://orders.newsfilecorp.com/files/7313/85013 3f66ee87e4b418a3 001full.jpg
GPOX has checked all of the necessary boxes for OTC Markets (at its sole discretion) to no longer view the Company as a shell risk. Moreover, GPOX has highlighted several other major accomplishments in the past 90 days:
Shell To Sell Interest In Deer Park Refinery To Partner Pemex
News provided by
Share this article
THE HAGUE, Netherlands, May 24, 2021 /PRNewswire/
Shell Oil Company, a subsidiary of Royal Dutch Shell plc, has reached an agreement for the sale of its interest in Deer Park Refining Limited Partnership, a 50-50 joint venture between Shell Oil Company and P.M.I. Norteamerica, S.A. De C.V. (a subsidiary of Petroleos Mexicanos, or Pemex). The transaction will transfer Shell s interest in the partnership, and therefore full ownership of the refinery, to Pemex, subject to regulatory approvals. Shell did not plan to market its interest in the Deer Park refinery; however, following an unsolicited offer from Pemex, we have reached an agreement to transfer our interest in the partnership to them, said Huibert Vigeveno, Shell s Downstream Director. Pemex has been our strong and active partner at the Deer Park Refinery for nearly 30 years, and we will continue to work with them in an
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.5 OF THE IRISH TAKEOVER RULES
FOR IMMEDIATE RELEASE
Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial Assets and Robust Clinical Pipeline with Multiple Near-term Inflection Points
Diversifies Revenue Base with Two Rapidly Growing Brands in Xeris Gvoke® and Strongbridge s KEVEYIS®